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OBJECTIVES We sought to find out whether dobutamine echocardiography (DbE) could provide
independent prediction of total and cardiac mortality, incremental to clinical and angio-
graphic variables.
BACKGROUND Existing outcome studies with DbE have examined composite end points, rather than death,
over a relatively short follow-up.
METHODS Clinical and stress data were collected in 3,156 patients (age 63 6 12 years, 1,801 men)
undergoing DbE. Significant stenoses (.50% diameter) were identified in 70% of 1,073
patients undergoing coronary angiography. Total and cardiac mortality were identified over
nine years of follow-up (mean 3.8 6 1.9). Cox models were used to analyze the effect of
ischemia and other variables, independent of other determinants of mortality.
RESULTS The dobutamine echocardiogram was abnormal in 1,575 patients (50%). Death occurred in
716 patients (23%), 259 of whom (8%) were thought to have died from cardiac causes.
Patients with normal DbE had a total mortality of 8% per year and a cardiac mortality of 1%
per year over the first four years of follow-up. Ischemia and the extent of abnormal wall
motion were independent predictors of cardiac death, together with age and heart failure. In
sequential Cox models, the predictive power of clinical data alone (model chi-square 115) was
strengthened by adding the resting left ventricular function (model chi-square 138) and the
results of DbE (model chi-square 181). In the subgroup undergoing coronary angiography,
the power of the model was increased to a minor degree by the addition of coronary anatomy
data.
CONCLUSIONS Dobutamine echocardiography is an independent predictor of death, incremental to other
data. While a normal dobutamine echocardiogram predicts low risk of cardiac death (on the
order of 1% per year), this risk increases with the extent of abnormal wall motion at rest and
stress. (J Am Coll Cardiol 2001;37:754–60) © 2001 by the American College of Cardiology
Dobutamine echocardiography (DbE) is an accurate alter-
native to exercise testing for the diagnosis of coronary artery
disease (CAD) in patients who are unable to exercise (1,2),
and it is also a valuable tool for the assessment of viable
myocardium (3,4). There are substantial data supporting the
use of this technique for prediction of short-term (i.e.,
perioperative) risk (5,6). However, most studies of the
prognostic implications of DbE in patients with stable
coronary disease have investigated the ability of the test to
predict composite end points over short-to-intermediate-
term follow-up (7).
In order to justify the cost of testing, it is important to
show that investigations alter outcome. The ability to
predict low risk would justify a conservative approach to
management in patients with a negative test. Conversely,
the demonstration that DbE adds information incremental
to clinical and resting data for the prediction of mortality
might have important implications for the selection of
different therapies. This could be especially important in
situations where anatomic data regarding coronary disease
extent are also available, in which case the results may justify
medical over interventional therapy. Given the relatively low
cardiac mortality of patients with stable chronic coronary
disease, such a study would require a large number of
patients followed over a significant duration. We, therefore,
established a multicenter study to address whether DbE
could independently identify the risk of cardiac and total
mortality and to examine the implications of a negative test
over prolonged follow-up. As increasing attention is being
paid to the appropriate indications for stress imaging, we
sought also to evaluate how to integrate the results with the
assessment of clinical risk and the findings of coronary
angiography.
METHODS
Study design. Between 1988 to 1994, 3,156 consecutive
patients (1,801 men and 1,355 women, age 63 6 12 years)
with known or suspected coronary disease underwent DbE
at the Cleveland Clinic Foundation or Indiana University.
Clinical characteristics and indications for testing were
recorded prospectively. Follow-up of all patients was ap-
proved by the Ethics Committee of the Cleveland Clinic
Foundation and was completed at the end of 1998.
From the *Department of Medicine, University of Queensland, Queensland,
Australia; the †Cleveland Clinic Foundation, Cleveland, Ohio; and ‡Indiana Uni-
versity, Indianapolis, Indiana. Supported, in part, by the American Society of
Echocardiography and the National Heart Foundation of Australia.
Manuscript received September 8, 2000; revised manuscript received October 16,
2000, accepted November 17, 2000.
Journal of the American College of Cardiology Vol. 37, No. 3, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(00)01191-8
Clinical evaluation. The most common indication for
testing was risk evaluation following infarction (23%) and
before noncardiac surgery (37%); 544 patients (17%) had
the test performed for the evaluation of chest pain. Known
CAD was present in 941 patients (30%), reflecting prior
myocardial infarction in 23% and revascularization in 6%.
Typical angina was present in 708 patients (23%); atypical
pain was present in 2,091 (66%), and the remaining 357
patients (11%) had no or noncardiac pain. The pretest
probability of CAD in those without known disease, deter-
mined on the basis of age, gender and symptom status (8)
was 55 6 24%. The risk of mortality at one year was 3.1 6
2.5%, based on a simple score obtained from the Duke
database involving the variables of age, chest pain, cardiac
history, risk factors and comorbidity (9). Risk factors were
highly prevalent with 58% of the patients having diabetes
and 42% having hypertension. An abnormal electrocardio-
gram was present in 71% of patients, most commonly due to
prior myocardial infarction.
Most patients (71%) were receiving medical therapy for
ischemic heart disease at the time of recruitment; 18% were
taking beta-adrenoceptor antagonists; 36% of patients re-
ceived calcium antagonists, and 19% of patients received
angiotensin-converting enzyme inhibitors. The combina-
tion of digoxin and diuretic therapy was used to define heart
failure requiring therapy.
DbE. A resting echocardiogram was performed in
parasternal and apical views and digitized on-line into a
quad-screen display. With the patient under continuous
clinical, electrocardiographic and echocardiographic moni-
toring, dobutamine was infused using a standard incremen-
tal dosing protocol from 5 to 40 mg/kg/min (1). The test
was terminated after completion of the final stage or earlier
if necessitated, by severe ischemia (severe angina, .2 mm
ST depression, extensive wall motion abnormalities), hyper-
tension (systolic blood pressure .220 mm Hg), hypoten-
sion (decrement of systolic blood pressure .20 mm Hg),
arrhythmias or side-effects intolerable to the patient. Over
most of the period of the original stress study (1988 to
1994), the administration of atropine had not yet become
standard practice (10). Therefore, a small proportion of
patients who failed to attain 85% of age-predicted maximal
heart rate at peak dose was administered atropine (1 mg
intravenous).
The study sought to address the prognostic value of the
test in routine practice, so the results of each study were
interpreted at the time of the original examination by
echocardiographers trained in stress echocardiography.
Resting left ventricular (LV) function was evaluated on the
basis of the extent of resting wall motion abnormalities as
normal, mild, moderately or severely impaired. Infarction
was recognized on the basis of akinesis or dyskinesis at rest.
Stress echocardiography was interpreted by comparison of
rest and stress images in a digitized quad-screen display.
Review of videotaped images was obtained, if desired, by the
interpreting physician, but the policy at each center was to
interpret the study independent of clinical, stress or angio-
graphic data. Segments with normal resting function with-
out any deterioration induced by dobutamine stress were
characterized as normal. Segments with a resting wall
motion abnormality that demonstrated augmentation of
function were considered viable, but this was not recognized
as a discrete response at the time of some of the initial
interpretations (1988 to 1994). Ischemia was identified in
the presence of a new or worsening wall motion abnormal-
ity. The extent of ischemia was classified as indicative of no,
one, two or three vessel CAD by combining the myocardial
segments into vascular territories. For this purpose, the
apex, anteroseptal, septal and anterior walls were attributed
to the left anterior descending, the lateral to the left
circumflex and the inferior and basal septal to the right
coronary. Because of the variable balance between the
circumflex and right coronary, the posterior wall was attrib-
uted to whichever was abnormal, based on involvement of
other segments, unless it was involved in isolation, in which
case it was ascribed to the circumflex vessel. A negative
study was characterized by a normal response in all seg-
ments, and a study was designated as abnormal if one or
more segments showed evidence of infarction or ischemia.
The results of the dobutamine echocardiograms were made
available to the physicians responsible for the patient.
Follow-up. Cardiac and total mortality were the primary
end points; hospital and physician records and death certif-
icates were used to ascertain the cause of death, which was
attributed to a cardiac etiology if a cardiac illness provoked
the final presentation or if death was sudden and unex-
pected. For the analysis of cardiac mortality, patients dying
from other causes were censored from follow-up at the time
of death. Coronary bypass surgery or coronary angioplasty
was not identified as a cardiac event, and patients were
censored at the time of these procedures.
Statistical analysis. The statistical analyses included de-
scriptive statistics (frequency and percentage of categorical
variables and mean and standard deviation of continuous
variables), Kaplan-Meier survival curves and Cox propor-
tional hazards models. Differences between survival curves
were compared with the log-rank test. All analyses were
performed using SPSS statistical software (SPPS Inc.,
Chicago, Illinois), and p values ,0.05 were considered to be
statistically significant. In the situation of making multiple
comparisons, significant p values were defined by the
Bonferroni method.
Abbreviations and Acronyms
CAD 5 coronary artery disease
DbE 5 dobutamine echocardiography
LV 5 left ventricular
SPECT 5 single photon emission computed tomography
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RESULTS
Dobutamine response. The end points of dobutamine
stress were comparable with those in the literature; 84% of
patients completed the protocol; the dose was limited by
side-effects in 9%, and 7% had the test stopped prematurely
due to ischemia. The patients attained 83 6 12% of
age-predicted maximal heart rate, and the peak rate-
pressure product was 19 6 5 3 103 beats 3 mm Hg.
Echocardiographic images were interpreted in all patients
who completed the test. Half of the patients had a normal
study. Of the remainder, 609 (19%) had a resting wall
motion abnormality alone; 517 (16%) showed ischemia, 166
(5%) viability, and 283 (9%) had a mixture of abnormalities.
Events during follow-up. Patients were followed for up to
nine years (mean 3.8 6 1.9 years), and follow-up data were
successfully obtained in 3,115 patients (99%). The total
mortality was 716 (23%), among whom death was attributed
to cardiac causes in 259 patients (8%). Myocardial revascu-
larization was performed in 332 patients who were censored
from follow-up at this time.
Association with total and cardiac mortality. The total
and cardiac survivals of patients with normal, ischemic and
scar findings at DbE are summarized in Figure 1. The
findings of DbE provide risk-stratification for total and
cardiac mortality. Moreover, the total extent of dysfunction
at peak stress is predictive of outcome (Fig. 2).
The risk of cardiac or any mortality conferred by DbE
findings relative to other variables is summarized in Table 1.
These multivariate models were derived from significant
univariate correlates of death, including clinical variables
(age, gender, diabetes, pretest probability of CAD, previous
myocardial infarction and revascularization, clinical risk),
medical treatment (digoxin, diuretics and angiotensin-
converting enzyme inhibitors), resting echocardiography
and stress variables (maximum heart-rate, peak systolic
blood pressure, rate-pressure product and ischemia). Rest-
ing LV dysfunction and inducible ischemia were indepen-
dent predictors of death.
Sequential models for the prediction of mortality were
devised to assess the incremental contribution of stress
echocardiography to clinical evaluation and resting assess-
ment of LV function (Fig. 3). For cardiac death, age, gender
and heart failure therapy entered the clinical model (chi-
square 132, p , 0.00001). The addition of resting LV
function increased the power of the model (chi-square 143,
p , 0.00001). The addition of stress testing data (extent of
ischemia and rate-pressure product) further increased the
power of the model (chi-square 157, p , 0.00001). The
same factors entered the clinical model for total mortality
(chi-square 200, p , 0.00001); the addition of resting LV
function again increased the power of the model (chi-square
271, p , 0.00001), which was increased further by stress
data (chi-square 292, p , 0.00001).
Outcome of patients with a negative dobutamine echo-
cardiogram. The outcome of the 1,581 patients with a
negative dobutamine echocardiogram is illustrated in Figure 1.
A normal study is associated with a cardiac mortality of
approximately 1% per year over the first four years of follow-
up, and this event rate accelerates slightly thereafter. The
difference between the average total mortality of 8% per year
and the cardiac mortality of 1% per year reflects the high
prevalence of comorbidity in these patients undergoing DbE.
Table 2 summarizes the features of 60 patients with a
normal study who died of cardiac causes during follow-up.
These patients were older and more likely to be receiving
therapy for heart failure than patients with a normal test but
having no events. In patients with heart failure but a
negative dobutamine echocardiogram, age ,65 years was
not associated with an increment of risk, but patients 65 to
75 years of age had a yearly cardiac mortality of 4%,
increasing to 6% yearly in patients .75 years old. Patients
with events were also more likely to have attained a lower
Figure 1. Kaplan-Meyer survival curves for the prediction of total (A) and
cardiac (B) mortality based on results of dobutamine echocardiography.
The outcome of patients with a normal scan was significantly different from
those with scar, ischemia or a mixed pattern.
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workload (rate-pressure product) although patients receiv-
ing beta-adrenergic blocking agents and calcium antagonist
therapy were comparable to those without events.
Integration with clinical data. Stress imaging tests have
become widely used, and the appropriateness of this testing
may be questioned. By correlating the initial clinical evalu-
ation with subsequent outcomes independent of other
predictors in the Cox model, we sought to identify a
low-risk group that might not need prognostic testing.
Neither pretest probability of coronary disease nor clinical
risk index was an independent determinant of outcome
(Table 1). Neither were the indications for testing the
source of significant variation in outcome. The group tested
for the assessment of viable myocardium had the most
adverse outcome (reflecting the presence of LV dysfunc-
tion), and those undergoing diagnostic evaluation for chest
pain fared the best (reflecting a proportion of patients
without coronary disease). No group could be identified in
this data set as being at low risk on clinical grounds,
reflecting appropriate selection for testing.
Integration with coronary angiography. The prognostic
value of DbE relative to coronary angiography was ad-
dressed in a subgroup of 1,073 patients who also underwent
coronary angiography within a year of the dobutamine
echocardiogram without an intervening procedure. Of these
individuals, 327 (31%) had no significant coronary disease;
218 (20%) had single-vessel disease, and 528 (49%) had
multivessel coronary disease. Sequential Cox regression
models were developed in this subgroup to reflect the
sequence of obtaining data in clinical practice. A model
using clinical variables only (age, heart failure and hyper-
Figure 2. Survival curves derived from the Cox model showing the relation
of extent of abnormal function at peak stress to outcome. The outcome of
patients with a normal scan was significantly different from those with
functional abnormalities of increasing severity (p , 0.0001).
Table 1. Independent Predictors of Total Cardiac Mortality Based on Clinical Variables and
Results of Dobutamine Echocardiography
Total Mortality Cardiac Mortality
RR (95% CI) p Value RR (95% CI) p Value
Age (yrs) 1.02 (1.01–1.03) , 0.0001 1.03 (1.02–1.04) , 0.0001
Male gender 1.28 (1.11–1.48) 0.001 1.49 (1.11–1.98) 0.007
Digoxin 1.44 (1.20–1.72) 0.0001 2.02 (1.46–2.80) 0.0001
Diuretic 1.35 (1.17–1.56) 0.0001 1.47 (1.09–1.98) 0.012
ACE inhibitors 1.70 (1.24–2.34) 0.0009
LV dysfunction (EF , 50%) 1.28 (1.19–1.37) 0.0001 2.60 (1.90–3.40) , 0.0001
Resting heart rate 1.01 (1.00–1.02) , 0.0001
Peak rate-pressure product , 15,000 1.30 (1.50–1.13) 0.0001
Ischemia by echocardiography 1.39 (1.20–1.62) 0.0001 1.83 (1.36–2.47) 0.0001
ACE 5 angiotensin-converting enzyme; CI 5 confidence interval; EF 5 ejection fraction; LV 5 left ventricular; RR 5 relative
risk.
Figure 3. Incremental value (expressed on y axis as model chi-square) of
dobutamine stress echocardiography results to clinical characteristics and
resting LV function for prediction of cardiac outcome. See text for
components of models. LV 5 left ventricular.
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tension) gave an overall chi-square of 43.2. Addition of
stress echocardiography (total extent score) increased this to
57.4, while adding angiography (number of involved vessels)
increased the chi-square further to 61.7 (Fig. 4).
DISCUSSION
This follow-up study of DbE addresses the ability of this
test to predict cardiac and total mortality. A negative
dobutamine echocardiogram accurately identifies low-risk
patients with a cardiac mortality of about 1% per year over
the first few years of follow-up, with a subsequent increase
reflecting the progression of coronary disease. This test is an
independent predictor of the risk of death, incremental to
clinical and resting echocardiographic data, and the degree
of risk parallels the increasing extent of abnormal function.
Indeed, the addition of angiographic data added little
prognostic power to the results of clinical evaluation and
stress echocardiography.
Identification of low-risk patients. The ability to detect
patients at low risk for cardiac events has been shown in
large trials using single photon emission computed tomog-
raphy (SPECT) imaging. Stress echocardiography is a
relatively younger technique, and the value of the test for
risk evaluation has been questioned (11). A number of
studies involving smaller numbers of patients and shorter
follow-up have now been published for dobutamine stress
echocardiography (12–22). The comparison of these studies
has been clouded by the use of different end points in
various studies, but in those that have examined cardiac
death or hard events, the yearly event rate with a negative
exercise or DbE has been on the order of 1% per year. These
findings are confirmed by our study, which also shows that,
in terms of total mortality, the group studied by DbE is at
high-risk for death, probably because of a high prevalence of
comorbidity. Our findings also show that the low-risk
“warranty” of a negative test is conferred for up to four years.
Later in follow-up, the cardiac events in individuals with a
negative test probably reflect the presence of progressive
coronary disease.
No test can be expected to be completely effective in
predicting freedom from subsequent events. In our experi-
ence, the predictors of events in individuals with a negative
Table 2. Predictors of Cardiac Death in Patients With Negative Dobutamine Echocardiograms
Univariate Multivariate
RR (95% CI) p Value RR (95% CI) p Value
Clinical
Age (yrs) 1.05 (1.03–1.07) , 0.0001 1.05 (1.03–1.07) , 0.0001
Male gender 1.42 (0.87–2.29) 0.16
Pretest probability of CAD 1.01 (1.00–1.02) 0.02
Angina 5.50 (0.70–41.5) 0.14
Previous coronary bypass 1.09 (0.40–3.01) 0.86
Previous myocardial infarction 1.19 (0.54–2.60) 0.66
Diabetes 1.46 (0.76–2.80) 0.25
Hypertension 5.0 (1.5–16.0) 0.009
One-year clinical risk 1.02 (1.01–1.03) 0.0003
Stress testing
Resting heart rate 1.01 (0.99–1.03) 0.009
Resting systolic blood pressure 1.01 (1.00–1.02) 0.05
Maximum heart rate 0.99 (0.98–1.00) 0.08
% age-predicted max heart rate 1.01 (0.99–1.04) 0.25
Peak systolic blood pressure 0.99 (0.98–1.00) 0.005
Peak rate-pressure product , 15,000 2.21 (1.35–3.63) 0.002 2.09 (1.27–3.45) 0.004
Therapy
Beta-adrenoceptor antagonists 0.65 (0.31–1.36) 0.25
Calcium antagonists 1.36 (0.84–2.22) 0.21
Long-acting nitrates 3.06 (0.96–9.77) 0.059
Digoxin 2.47 (1.34–4.53) 0.004 1.93 (1.04–3.60) 0.04
Diuretic 1.50 (0.91–2.47) 0.111
ACE inhibitors 2.0 (1.17–3.39) 0.011 2.05 (1.19–3.51) 0.01
ACE 5 angiotensin-converting enzyme; CAD 5 coronary artery disease; CI 5 confidence interval; RR 5 relative risk.
Figure 4. Incremental value (expressed on y axis as model chi-square) of
dobutamine stress echocardiography results to clinical characteristics and
coronary angiography for prediction of cardiac outcome. Multivariate
analysis of independent predictors of outcome in 1,073 patients who
underwent dobutamine echocardiography and coronary angiography.
DbE 5 dobutamine echocardiography.
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test include increasing age and heart failure. In previous
work examining composite end points, “false negative”
exercise echocardiograms were also predicted by low-
workload, anginal symptoms despite the absence of identi-
fiable wall motion abnormalities and left ventricular hyper-
trophy (23).
Stratification of risk in patients with positive tests. Even
in the era before current therapy, patients with stable
chronic coronary disease were reported to have a relatively
low cardiac mortality of 4% per year (24). Our findings
indicate that the presence and extent of abnormalities at
stress echocardiography is incremental to clinical variables
in the prediction of cardiac events.
Clinical factors have been shown to quite effectively
identify risk in patients with stable CAD (25), and the use
of clinical scores to identify patients at the extremes of risk
on clinical grounds may help to avoid inappropriate inves-
tigations. However, the impact of clinical risk status has
been better evaluated in the nuclear literature than with
echocardiography (26–28). Our findings are that, although
clinical risk is a predictor of outcome, it is not possible to
identify a low-risk group other than those at low probability
for CAD on diagnostic grounds.
The extent and severity of perfusion defects have been
shown to correlate very well with the outcomes of patients
studied using SPECT, among which the strongest predictor
is the extent of malperfused tissue (29), reflecting both the
extent and severity of rest- and stress-perfusion defects. The
results of this study indicate that an analogous measure of
the number of ischemic and infarcted vascular territories is
predictive of outcome using DbE. The ability to identify a
spectrum of risk may facilitate the selection of medical and
interventional treatments; indeed, arguments have been
made against the use of interventions in individuals with
small fixed or reversible SPECT defects.
Prognostic implications relative to angiographic data.
The prognostic implications of DbE relative to coronary
angiography were studied in a subgroup of 1,073 patients
who underwent coronary angiography. The benign prog-
nostic implications of a negative DbE may alleviate clini-
cians’ concern regarding “false negative” stress echocardio-
grams and reduce the rate of angiography in patients with
ongoing symptoms but negative stress tests. The addition of
the angiographic data to the clinical and stress data in-
creased the ability to predict cardiac outcomes. This analysis
could have been influenced by the process of censoring
patients who underwent revascularization, because this par-
ticular group would have undergone angiography. On the
other hand, these individuals may have their natural history
altered by intervention, which would reduce the event rate
and, therefore, the predictive power of each diagnostic
technique.
Interpretation of stress echocardiography. The interpre-
tation of regional wall motion is currently based on the
qualitative interpretation of regional wall motion abnormal-
ities, and this subjective approach, together with the use of
multiple observers, was used to mimic the behavior of the
test in daily practice. Data on interobserver variability were
not gathered for this study; previous work has suggested that
observers at each center share an interpretation style (30).
The sites selected for this study have a concordant reading
style, reflecting previous training and teaching collaboration
so that interinstitution discordance (31) was not considered
to be an important factor. Finally, as in other multicenter
stress-imaging studies (26,32), we sought to simplify assess-
ment of disease extent into involvement of coronary vascular
territories rather than selecting a more complicated score in
order to enhance the wide applicability of the results.
Cardiac and total mortality. Although recent work from
the nuclear imaging literature has focused on the prediction
of cardiac death (27,28), this approach is subject to prob-
lems of ascertainment between cardiac and noncardiac
mortality. The accuracy of this approach has been recently
criticized (33), and, although the overall 2% cardiac mor-
tality in this study is within the expected range for chronic
stable CAD, the overall 6% total mortality may be due to
misrepresentation of some deaths as noncardiac as well as
the high prevalence of comorbidity. Because of the advan-
tages and disadvantages of each approach, we have ex-
pressed both total and cardiac mortality. The retention of
cardiac death as a focus of the paper facilitates comparison
with the older literature and addresses the likelihood of
many noncardiac deaths among older patients with multiple
comorbidities.
Study limitations. An inherent limitation of follow-up stud-
ies is that they reflect the performance of a technique as it was
applied years before the completion of the study. This meth-
odologic drift is apparent in this study, which involved admin-
istration of currently standard doses of dobutamine, but largely
without the addition of atropine. Use of atropine might have
led to the identification of additional patients with coronary
disease, with reduction in the number of patients having events
after a negative scan. A related problem might be termed
diagnostic drift—by intention, the data gathered in this study
were the original test interpretations to reflect the behavior of
the test in clinical practice. However, this precluded the
recognition of myocardial viability in many patients,
which was not widely recognized during DbE until later
in the study period. Finally, the test results may have
influenced the clinical management of patients, especially
decisions to perform revascularization. The revasculariza-
tion of patients with positive test results likely reduced
the prognostic power of ischemia, as patients were
censored at the time of this procedure.
Conclusions. Dobutamine echocardiography provides
prognostic information regarding total and cardiac mortal-
ity, independent and incremental to standard predictors of
outcome. Assessment of the extent of ischemia and clinical
variables may be used to make outcome-based decisions
regarding patient management.
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